Skip to main content
Clinical Trials/NCT04235712
NCT04235712
Completed
Not Applicable

Implementation of Harmonized Depression Outcome Measures in a Health System to Support Patient-Centered Outcomes Research

OM1, Inc.1 site in 1 country5 target enrollmentNovember 17, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Major Depression
Sponsor
OM1, Inc.
Enrollment
5
Locations
1
Primary Endpoint
Suicide Ideation and Behavior
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Working with a health system, the investigators will recruit practices to participate in the pilot study, consent and enroll patients with major depressive disorder, and collect the PHQ-9 from those patients at three timepoints (baseline, 6 months post-enrollment, and 12 months post-enrollment). The PHQ-9 will be captured either at an office visit or directly from patients. The investigators will build and implement an open-source SMART on FHIR app to collect key data from the EHR, combine that data with the PHQ-9 results, and present the measurements back to the clinicians. The investigators will then obtain feedback from clinicians on the value and usefulness of the app.

Detailed Description

The study is a longitudinal, observational pilot study that will assess the utility and value displaying the harmonized outcomes data to clinicians in the clinical workflow using an open-source, SMART on FHIR app. The app will connect with the site EHR, aggregate EHR and PRO data, calculate the outcome measure results, and return the results to the EHR so that they are viewable within the clinician workflow. Baseline data on patient characteristics, treatments, and symptoms will be combined with longitudinal data on outcomes during the study timeframe. All data will be collected from institution electronic medical records (EMRs), PRO portals, and other existing data sources, as needed.

Registry
clinicaltrials.gov
Start Date
November 17, 2020
End Date
May 15, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
OM1, Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients age 18 and older
  • Diagnosis of major depression or dysthymia
  • Willing and able to provide informed consent

Exclusion Criteria

  • There are no exclusion criteria for this study.

Outcomes

Primary Outcomes

Suicide Ideation and Behavior

Time Frame: 12 months post baseline (+/- 60 days)

Selection of 'several days', 'more than half the days' or 'nearly every day' option on Patient Health Questionnaire-9 item 9 ("Thoughts that you would be better off dead or of hurting yourself in some way") and/or documentation of nonfatal suicide attempts/suicide attempt behaviors, planning/preparatory acts, or active suicidal ideation extracted from data routinely recorded in the Electronic Medical Record. A higher score means more severe depression.

Death from suicide

Time Frame: 12-month intervals

Patient age 18 or older with a diagnosis of major depression or dysthymia who died from suicide, reported in 12-month intervals.

Improvement in Depressive Symptoms: Remission

Time Frame: 12 months post baseline (+/- 60 days)

Patient Health Questionnaire-9 score \> 9 who demonstrates remission defined as a Patient Health Questionnaire-9 score less than 5. Patient Health Questionnaire scores range from 0 to 27. A higher score means more severe depression.

Improvement in Depressive Symptoms: Response

Time Frame: 12 months post baseline (+/- 60 days)

Patient age 18 or older with a diagnosis of major depression or dysthymia and an initial Patient Health Questionnaire-9 score \> 9 who demonstrates a response to treatment defined as a Patient Health Questionnaire-9 score that is reduced by 50% or greater from the initial Patient Health Questionnaire-9 score. Patient Health Questionnaire scores range from 0 to 27. A higher score means more severe depression.

Adverse Events

Time Frame: 12 months post baseline (+/- 60 days)

Depression treatment-related adverse events, captured using the Frequency, Intensity, and Burden of Side Effects Ratings scale where available and extracted from data routinely recorded in the Electronic Medical Record. The Frequency, Intensity, and Burden of Side Effects Ratings score ranges from 0 to 6. A higher score means more of a burden.

Worsening in Depressive Symptoms: Recurrence

Time Frame: 12 months post baseline (+/- 60 days)

Patient age 18 or older with a diagnosis of major depression or dysthymia and an initial Patient Health Questionnaire-9 \> 9 who demonstrates remission (defined as a Patient Health Questionnaire-9 score \< 5) of at least two months' duration and subsequently experiences a recurrence of a depressive episode, defined as a Patient Health Questionnaire-9 score \> 9 OR hospitalization for depression or suicidality. Patient Health Questionnaire scores range from 0 to 27. A higher score means more severe depression.

Study Sites (1)

Loading locations...

Similar Trials